Skip to main content

Navigation principale

  • About
  • Team
  • Portfolio
  • Strategy
  • ESG
  • Testimonials
  • News
  • Contact

Secondary Navigation

  • Fr
  • En

Actualités

You are here

  • Home
  • Actualités
Tessares

GO Malta provides innovative services using hybrid fixed and mobile converged solution

Post date
13/09/2019

GO plc in Malta has launched a converged fixed and mobile solution using Tessares’s Multipath TCP technology.  Available to all GO plc customers, this solution combines the operator's fixed network

Read more
Botalys

Botalys, the specialized Walloon producer in natural ginseng, raises 3 million euros and goes into industrial phase in Ath

Post date
09/01/2019

After a first order of its flagship product - the best dry ginseng in the world - in May 2018, Pierre-Antoine Mariage and Paul-Evence Coppée are expanding internationally thanks to important contracts

Read more
iteos

VIVES portfolio company iTeos Therapeutics, a spin-off of UCLouvain and LICR, strengthened by an oversubscribed Series B fundraising of 64 million euros

Post date
20/06/2018

VIVES, a long-standing investor in iTeos Therapeutics, participated in the Series B €64 million fundraise. The lead and new investor, the American fund MPM Capital, will allow the UCLouvain spin-off

Read more
a-Mansia

A-Mansia Biotech S.A. closes a €13m Series A financing round catalysed by the initial support of VIVES

Post date
27/04/2018

A-Mansia Biotech S.A. is active in the microbiome field based on pioneering research on Akkermansia muciniphila (A. muciniphila) from two well-known scientists, Prof. P. Cani (Université catholique de

Read more
tessares

Proximus, VIVES II and SRIW participate in a €3 million funding round in Tessares

Post date
22/03/2018

Proximus and VIVES II, existing shareholders of Tessares, are thereby strengthening their participation and are joined by the SRIW which is also participating. The amount raised is aimed at speeding

Read more
syndesi

UCB and Investor Syndicate Led by Novo Seeds Launch Syndesi Therapeutics to Develop Novel Therapeutics for Cognitive Disorders

Post date
05/02/2018
  • Syndesi Therapeutics to leverage UCB’s expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism
  • Series A financing of €17 M
Read more
Aphea

Aphea.Bio raises 9 million euros in funding. Aphea.Bio aims at leading position in next generation agricultural biologicals

Post date
26/06/2017

Louvain-la-Neuve, 26th June 2017 - Aphea.Bio, spin-off of the VIB, UGent and KU Leuven, will develop sustainable agricultural products based on nature-based microorganisms to increase crop yield and

Read more

Pagination

  • First page « First
  • Previous page ‹‹
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
 

VIVES Funds

VIVES Partners
Chemin du Stocquoy, 1
1300 Wavre
Belgium

Email
info@vivesfund.com
GSM
+32 472 206 355

Contact

Please note that VIVES only invests in companies located in Europe.
Maximum 5 files.
256 MB limit.
Allowed types: txt, rtf, pdf, doc, docx, odt, ppt, pptx, odp, xls, xlsx, ods.
Lire la politique générale de protection des données personnelles.

VIVES is a multi-sector technology fund that invests in spin-offs from UCLouvain and start-ups in Belgium and neighboring countries. The fund has the ability to invest at different stages of a company's development: seed, start-up and growth.

Menu Pied de page

  • Privacy policy & cookies
  • Terms & conditions
  • © 2025 All rights reserved.
  • Website by Visible